Endocytoscopy can identify dysplasia in aberrant crypt foci of the colorectum: a prospective in vivo study

Cipolletta, Livio; Bianco, Maria Antonia; Rotondano, G.; Piscopo, Raffaele; Meucci, C.; Prisco, A.; Cipolletta, F.; Gregorio, Amelie de; Salvati, A

doi:10.1055/s-0028-1103452

Cited by 42 publications

(30 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Subsequently, several investigators have confirmed our proposal of the ACF-adenoma-carcinoma sequence through demonstrating a close relationship between ACF and adenomas or cancers in terms of number, size, and pathologic features (14)(15)(16)(17)(18)(19).…”

Section: Introductionmentioning

confidence: 71%

Randomized Double-Blind Trial of Sulindac and Etodolac to Eradicate Aberrant Crypt Foci and to Prevent Sporadic Colorectal Polyps

Takayama

Nagashima

Maeda

et al. 2011

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: On the basis of the results of our preliminary trial suggesting that aberrant crypt foci (ACF) could be eradicated by short-term administration of sulindac, in the present study, we explored the feasibility of using ACF as surrogate markers for chemoprevention of colorectal cancer.Experimental design: Randomly assigned to sulindac (300 mg daily), etodolac (400 mg daily), and placebo groups were 189 subjects without polyps or who had undergone polypectomy. Drugs were administered for 2 months. ACF in the rectal region were counted by magnifying endoscopy. Occurrence of polyps was evaluated at 12 months. A planned interim analysis was conducted.Results: ACF number at 2 months was significantly suppressed in the sulindac group (P ¼ 0.0075), but not in the etodolac group (P ¼ 0.73). In the sulindac group, the numbers of adenomas plus hyperplastic polyps (total polyps) and adenomas at 12 months were significantly (P ¼ 0.02) and marginally (P ¼ 0.064) lower, respectively, in comparison with the placebo group; no such difference was observed in the etodolac group. In analysis of only polypectomized subjects, the numbers of total polyps and adenomas in the sulindac group were even more markedly lower, with P values of 0.014 and 0.034, respectively. A similar tendency was confirmed by analyses of the incidence of polyps at 12 months. Suppression rates of total polyps and adenomas in ACF responders to sulindac were significantly greater than in nonresponders. In all groups, compliance was more than 90% and no intolerable adverse effects were observed.Conclusions: ACF may be useful as surrogate lesions for chemoprevention of colorectal cancer. Clin Cancer Res; 17(11); 3803-11. Ó2011 AACR.

show abstract

Section: Introductionmentioning

confidence: 71%

Randomized Double-Blind Trial of Sulindac and Etodolac to Eradicate Aberrant Crypt Foci and to Prevent Sporadic Colorectal Polyps

Takayama

Nagashima

Maeda

et al. 2011

Clinical Cancer Research

View full text Add to dashboard Cite

show abstract

“…Different studies suggest the potential of endocytoscopy for the in vivo evaluation of duodenal mucosa in celiac disease [21] . Furthermore, endocytoscopy was able to detect tissue abnormalities in normal mucosa surrounding colorectal cancer and to identify neoplasia in aberrant crypt foci [22] . Additionally, endocytoscopy was shown to distinguish neoplastic from non-neoplastic lesions, and also to differentiate invasive colon cancer from adenoma [23,24] .…”

mentioning

confidence: 99%

“…Recently, endocytoscopy has been established as a useful tool to examine mucosal surfaces [20][21][22][23] . Different studies suggest the potential of endocytoscopy for the in vivo evaluation of duodenal mucosa in celiac disease [21] .…”

mentioning

confidence: 99%

New endoscopic approaches in IBD

Neumann

Neurath²,

Mudter³

2011

WJG

View full text Add to dashboard Cite

Recent advances in endoscopic imaging techniques have revolutionized the diagnostic approach of patients with inflammatory bowel disease (IBD). New, emerging endoscopic imaging techniques visualized a plethora of new mucosal details even at the cellular and subcellular level. This review offers an overview about new endoscopic techniques, including chromoendoscopy, magnification endoscopy, spectroscopy, confocal laser endomicroscopy and endocytoscopy in the face of IBD.

show abstract

“…Multiple-step procedures including extensive washing followed by methylene blue staining are time consuming and considered as the disadvantage of ECS in the cytological/ architectural observation for GI neoplasms. 16 However, extensive washing is not necessary to observe amebic trophozoites because they are usually found in the mucus on the surface of aphthae. In other words, excessive washing may rather reduce the possibility of finding residual trophozoites.…”

Section: Discussionmentioning

confidence: 99%

In vivo visualization of trophozoites in patients with amoebic colitis by using a newly developed endocytoscope

Hosoe¹,

Kanai²,

Bessho³

et al. 2010

Gastrointestinal Endoscopy

View full text Add to dashboard Cite

Endocytoscopy can identify dysplasia in aberrant crypt foci of the colorectum: a prospective in vivo study

Abstract: Endocytoscopy provides real-time histological images in vivo, with clear visualization of cellular details and features of dysplasia in colorectal ACF.

Cited by 42 publications

References 11 publications

Randomized Double-Blind Trial of Sulindac and Etodolac to Eradicate Aberrant Crypt Foci and to Prevent Sporadic Colorectal Polyps

Randomized Double-Blind Trial of Sulindac and Etodolac to Eradicate Aberrant Crypt Foci and to Prevent Sporadic Colorectal Polyps

New endoscopic approaches in IBD

In vivo visualization of trophozoites in patients with amoebic colitis by using a newly developed endocytoscope

Contact Info

Product

Resources

About